BioCardia Stock (NASDAQ:BCDA)
Previous Close
$2.03
52W Range
$1.84 - $10.95
50D Avg
$2.56
200D Avg
$4.15
Market Cap
$9.12M
Avg Vol (3M)
$844.92K
Beta
1.27
Div Yield
-
BCDA Company Profile
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
BCDA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| MLYS | Mineralys Therapeutics, Inc. |
| ABVC | ABVC BioPharma, Inc. |
| KTTA | Pasithea Therapeutics Corp. |
| AVTE | Aerovate Therapeutics, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| ERAS | Erasca, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| RZLT | Rezolute, Inc. |
| INDP | Indaptus Therapeutics, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| PTIX | Protagenic Therapeutics, Inc. |
| FBRX | Forte Biosciences, Inc. |